Journal of internal medicine · 2025
Colchicine and cardiovascular events: An updated meta-analysis of published randomized controlled trials.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xie Sining, Galimberti Federica, Olmastroni Elena, Catapano Alberico L, Casula Manuela
Аннотация
BACKGROUND: Colchicine shows promise in reducing cardiovascular risk, but a recent study raised the question whether this is really the case. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess its impact on cardiovascular outcomes in secondary prevention.
METHODS: We systematically searched major databases up to March 2025 for RCTs comparing colchicine to placebo over a treatment duration of ≥12 months, reporting major adverse cardiovascular events (MACEs). Both fixed- and random-effects models were used to compute pooled risk ratios (RRs) and 95% confidence intervals.
RESULTS: Six RCTs comprising 21,774 patients were included. Colchicine significantly reduced the risk of MACEs (RR 0.74 [0.60-0.92]) and specific components of primary outcome (myocardial infarction, RR 0.85 [0.73-0.98]; stroke, RR 0.79 [0.65-0.95]), with no significant effect on cardiac death and revascularization.
CONCLUSION: These results support the efficacy of low-dose colchicine in reducing MACEs when added to standard care for at least 12 months.
METHODS: We systematically searched major databases up to March 2025 for RCTs comparing colchicine to placebo over a treatment duration of ≥12 months, reporting major adverse cardiovascular events (MACEs). Both fixed- and random-effects models were used to compute pooled risk ratios (RRs) and 95% confidence intervals.
RESULTS: Six RCTs comprising 21,774 patients were included. Colchicine significantly reduced the risk of MACEs (RR 0.74 [0.60-0.92]) and specific components of primary outcome (myocardial infarction, RR 0.85 [0.73-0.98]; stroke, RR 0.79 [0.65-0.95]), with no significant effect on cardiac death and revascularization.
CONCLUSION: These results support the efficacy of low-dose colchicine in reducing MACEs when added to standard care for at least 12 months.